PureTech Adds Bharatt Chowrira, PureTech s President and Chief of Business and Strategy, to Board of Directors
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors as an executive director. Dr. Chowrira has served as PureTech s President and Chief of Business and Strategy since March 2017 and will continue in that role as an executive director of the Company. Dr. Chowrira s appointment is effective from February 1, 2021. Bharatt has made a big impact since joining PureTech in 2017 and he continues to make key contributions as we advance our clinical pipeline toward key value-driving milestones, said Daphne Zohar, Founder and Chief Executive Officer of PureTech
Details of the Offer The Company highly values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Offer. The Company is therefore making the Offer available exclusively through PrimaryBid.com. The Offer is offered under the exemptions against the need for a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority in its capacity as the UK Listing Authority. The Offer is not being made into any Restricted Jurisdiction or any other jurisdiction where it would be unlawful to do so.
MBH Corporation PLC accelerates pace of acquisitions as strategy develops proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
+44 (0) 207 496 3000
The Company highly values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Offer. The Company is therefore making the Offer available exclusively through PrimaryBid.com.
The Offer is offered under the exemptions against the need for a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority in its capacity as the UK Listing Authority. The Offer is not being made into any Restricted Jurisdiction or any other jurisdiction where it would be unlawful to do so.
Xeros Technology Group plc develops and licenses platform technologies which transform the sustainability, performance and economics of water intensive industrial and commercial processes. Xeros patented XOrb™ technologies significantly reduce the amount of water used in the dyeing, finishing or laundering of soft substrates such as garments and fabrics. They enable the remaining water to become far more efficient and effective in either affixing or removing molecules, the result being improvements in economic, operational, product and sustainability outcomes. The Group is applying its technology in the fields of apparel manufacturing, tanning and commercial and domestic laundry. Xeros XDrum™ technology is a patented, simple, low cost machine drum design which enables XOrbs to be introduced into and subsequently removed from process cycles in Xeros chosen fields. The design provides Original Equipment Manufacturers ( OEMs ) with